Search Results
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
pharmacokinetics and pharmacodynamics of ASC36 following single and multiple ascending oral doses in 86 participants with obesity (body mass index (BMI) ≥ 30.0 kg/m²) or overweight (BMI ≥ 27.0 kg/m²)."In 2026, we initiated four Phase I studies for our peptide pipeline, including ASC36 oral tablets, our fourth
More news about: Ascletis Pharma Inc.
Sep 04, 2026, 06:12 ET GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly
12 to 17), at 0.6 percent and 0.9 percent, respectively. An estimated 20 percent of children in the US have obesity, meaning their body mass index (BMI) is above the 95th percentile for children of similar age and sex, without having diabetes, a well-known complication of the disease.Publishing
More news about: NYU Langone Health System
Aug 31, 2026, 09:43 ET In HelloNation, Medical Weight Loss Expert Susan Stivalo Explains Who Is a Good Candidate for Medical Weight Loss Programs
with a BMI of 27 or higher may also qualify when weight-related conditions such as type 2 diabetes, high blood pressure, or sleep apnea are present. These BMI requirements help providers identify individuals who may be at increased risk due to excess weight.The article emphasizes that BMI requirements
More news about: HelloNation
Aug 31, 2026, 07:00 ET New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
weight-related comorbidity,1,2 which is often associated with poorer treatment outcomes.3-5 At baseline, the mean body mass index (BMI) of participants was 39.2 in TOGETHER-PsO and 37.6 in TOGETHER-PsA."Psoriatic disease is often accompanied by obesity or overweight, which can
More news about: Eli Lilly and Company
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
NCT07743463): A pivotal trial evaluating efficacy and safety of once-daily oral ASC30 in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 with at least one weight-related comorbidity), excluding type 2 diabetes. Participants are randomized to
More news about: Ascletis Pharma Inc.
Aug 26, 2026, 06:45 ET Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
million individuals enrolled in U.S. healthcare plans. The analysis included 15,843 adults aged above 55 (mean age 64.5 years) with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one obesity-related complication, who initiated Zepbound between November 2023 and September 2025. Each Zepbound
More news about: Eli Lilly and Company
Aug 19, 2026, 14:00 ET The Digital Imaging Channel Tops 700 Subscribers on YouTube
https://www.bmiimaging.com.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems converts paper, microfilm, microfiche, and other analog records into secure, searchable digital collections, and then helps organizations store and access those records. BMI offers public, private, and CJIS-compliant
More news about: BMI Imaging Systems, Inc.
Aug 18, 2026, 12:15 ET SOZO® Digital Health Platform Receives FDA Clearance for Sarcopenia Risk Assessment
CancerFitness.org and a Past-President of the American Society of Breast Surgeons (ASBrS).Muscle loss can hide behind a stable weight or a normal BMI. SOZO's muscle-mass indices give clinicians the clarity to separate muscle from fat. Because those indices track muscle health over time, clinicians
More news about: ImpediMed
Aug 10, 2026, 07:00 ET Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
pharmacodynamics of ASC36_35FDC injections following single and multiple ascending doses in participants with obesity (body mass index (BMI) ≥ 30.0 kg/m²) or overweight (BMI ≥ 27.0 kg/m²) with weight-related comorbidities. The Phase I study also evaluates two different FDC formulations: Injection A in 88
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 02:55 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with SBS Law
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BMI during the class period listed are encouraged
More news about: Schall, Brown & Schwartz LLP
Aug 03, 2026, 01:42 ET Badger Meter, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BMI
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BMI during the class period listed are encouraged
More news about: DJS Law Group LLP
Aug 02, 2026, 06:17 ET Badger Meter Deadline Tomorrow: BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit
Aug. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Jul 31, 2026, 03:59 ET Badger Meter, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BMI
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BMI during the class period listed are encouraged
More news about: DJS Law Group LLP
Jul 31, 2026, 02:36 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with SBS Law
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BMI during the class period listed are encouraged
More news about: Schall, Brown & Schwartz LLP
Jul 30, 2026, 08:32 ET New Clinical Research Presented at NUTRITION 2026 Shows Superbrewed Food's Postbiotic Cultured Protein Matches Whey in Muscle-Building Response
StudyThe single-blind, randomized, placebo-controlled crossover study enrolled 10 healthy adults (5 women, 5 men; mean age 31.4 ± 5.3 years; BMI 25.2 ± 4.0) at Texas A&M University. Following a screening visit, each participant completed four non-consecutive study days, separated by at least
More news about: Superbrewed Food Inc.
Jul 29, 2026, 16:05 ET Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
various VK2735 maintenance dosing regimens. This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for an induction period, after which participants
More news about: Viking Therapeutics, Inc.
Jul 29, 2026, 14:55 ET GRAMMY AWARD-WINNING RAP ICON NAS TO RECEIVE THE BMI ICON AWARD AT THE 2026 BMI R&B/HIP-HOP AWARDS
BMI announced today that GRAMMY-award winning rap icon Nas will receive the BMI Icon Award at the 2026 BMI R&B/Hip-Hop Awards on Wednesday, August 26 in Los Angeles, CA. Nas
More news about: Broadcast Music, Inc. (BMI)
Jul 29, 2026, 10:56 ET Research Published in Mayo Clinic Proceedings: Digital Health Reveals Body Composition Predicts GLP-1 Weight Loss Outcomes
starting body composition predicts itThe study's most original finding is that, among all the baseline factors it looked at (age, gender, BMI, and muscle-to-fat ratio), your starting muscle-to-fat ratio was the most consistent signal of weight-loss quality. People who start with more fat relative
More news about: Withings
Jul 29, 2026, 06:59 ET Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
increased risk of serious cardiovascular events. Gwyn Lo is contraindicated in women with a BMI ≥ 30 kg/m2. The risk of VTE may be greater with Gwyn Lo in women with a BMI > 30 kg/m2 compared to women with a lower BMI. Patients should discuss their medical history and risk factors with their healthcare provider
More news about: Viatris Inc.
Jul 28, 2026, 20:59 ET BMI Deadline: BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.So what: If
More news about: THE ROSEN LAW FIRM, P. A.
Jul 28, 2026, 18:54 ET Badger Meter, Inc. (BMI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BMI). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BADGER METER, INC. (BMI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 3, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD
More news about: Law Offices of Howard G. Smith
Jul 28, 2026, 10:07 ET BMI Shareholder Alert: Badger Meter, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
July 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Badger Meter, Inc. (NYSE: BMI).
More news about: The Gross Law Firm
Jul 28, 2026, 09:54 ET BADGER METER, INC. (NYSE: BMI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by August 3, 2026
Berger Montague PC announces a class action lawsuit against Badger Meter, Inc. (NYSE: BMI) ("Badger Meter" or the "Company") on behalf of investors who purchased or acquired Badger Meter common stock during the period from April 18, 2024
More news about: Berger Montague
Jul 28, 2026, 03:58 ET Badger Meter, Inc. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuit
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: Schall, Brown & Schwartz LLP
Jul 27, 2026, 17:58 ET Badger Meter, Inc. (BMI) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BMI) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles